|

Efficacy and Safety of Telmisartan Compared With Losartan

RECRUITINGPhase 4Sponsored by Chong Kun Dang Pharmaceutical
Actively Recruiting
PhasePhase 4
SponsorChong Kun Dang Pharmaceutical
Started2023-04-19
Est. completion2025-10-31
Eligibility
Age19 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06431477

Summary

A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension

Eligibility

Age: 19 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Male of Female subjects aged ≥19 or \<75
* Type II Diabetes Mellitus subjects who have been taken medicine
* Subjects who have voluntarily decided to participate in this clinical trial and Signed ICF

Exclusion Criteria:

* Subjects with Type I Diabetes Mellitus
* Subjects with Primary hyper-aldosteronism
* Subjects with a history of drug or alcohol abuse or suspected patient within 1 year as of the time of screening
* Pregnant women, lactating women, or subjects who do not agree to use appropriate contraception during the clinical trial period
* Subjects who received other clinical trial drugs within 28 days of screening visit
* Subjects who are unable to participate in this clinical trial at the discretion of the investigator.

Conditions3

DiabetesDiabetic NephropathiesHypertension

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.